Skip to main content

MARIMED INC

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

MRMDStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

December 31,
20232022
Assets
Current assets:
Cash and cash equivalents$14,645$9,737
Accounts receivable, net7,1994,157
Inventory25,30619,477
Deferred rents receivable630704
Notes receivable, current portion522,637
Investments, current portion88123
Due from related parties10529
Other current assets3,4077,282
Total current assets51,43244,146
Property and equipment, net89,10371,641
Intangible assets, net17,01214,201
Goodwill11,9938,079
Investments, net of current portion221—
Notes receivable, net of current portion8147,467
Operating lease right-of-use assets9,7164,931
Finance lease right-of-use assets3,295713
Other assets12,5371,024
Total assets$196,123$152,202
Liabilities, mezzanine equity and stockholders’ equity
Current liabilities:
Mortgages and notes payable, current portion$723$3,774
Accounts payable9,0016,626
Accrued expenses and other3,5493,091
Income taxes payable14,43411,489
Operating lease liabilities, current portion1,9451,273
Finance lease liabilities, current portion1,210237
Total current liabilities30,86226,490
Mortgages and notes payable, net of current portion65,65225,943
Operating lease liabilities, net of current portion8,4554,173
Finance lease liabilities, net of current portion2,140461
Other liabilities100100
Total liabilities107,20957,167
Commitments and contingencies
December 31,
20232022
Mezzanine equity:
Series B convertible preferred stock, $0.001 par value; 4,908,333 shares authorized, issued and outstanding at December 31, 2023 and 202214,72514,725
Series C convertible preferred stock, $0.001 par value; 12,432,432 shares authorized; 1,155,274 and 6,216,216 shares issued and outstanding at December 31, 2023 and 2022, respectively4,27523,000
Total mezzanine equity19,00037,725
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value; 32,659,235 shares authorized; zero shares issued and outstanding at December 31, 2023 and 2022——
Common stock, $0.001 par value; 700,000,000 shares authorized; 375,126,352 and 341,474,728 shares issued and outstanding at December 31, 2023 and 2022, respectively375341
Common stock subscribed but not issued; zero and 70,000 shares at December 31, 2022 and 2021, respectively—39
Additional paid-in capital171,144142,365
Accumulated deficit(99,955)(83,924)
Noncontrolling interests(1,650)(1,511)
Total stockholders’ equity69,91457,310
Total liabilities, mezzanine equity, and stockholders’ equity$196,123$152,202
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.